Huntington National Bank Sells 8,660 Shares of Abbott Laboratories $ABT

Huntington National Bank reduced its holdings in Abbott Laboratories (NYSE:ABT) by 2.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 390,804 shares of the healthcare product maker’s stock after selling 8,660 shares during the quarter. Huntington National Bank’s holdings in Abbott Laboratories were worth $48,964,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. Capital International Investors grew its holdings in shares of Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after buying an additional 1,478,076 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Abbott Laboratories by 3.8% in the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after purchasing an additional 499,351 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Abbott Laboratories by 7.2% in the third quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock valued at $1,727,869,000 after purchasing an additional 864,531 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of analyst reports. Oppenheimer decreased their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Stifel Nicolaus decreased their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Jefferies Financial Group decreased their price target on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, TD Cowen decreased their price target on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $119.09.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott won FDA clearance and EU CE Mark approval for Ultreon 3.0, an AI-powered coronary imaging tool that helps guide artery stent placement, which could support future med-tech growth. Abbott (ABT) Wins FDA and EU Approval for an AI-Powered Tool That Guides Artery Stent Placement
• Positive Sentiment: The company secured CE Mark for Libre Duo, the world’s first dual glucose-ketone sensing technology, expanding its diabetes care lineup and potentially strengthening its CGM franchise. Abbott secures CE Mark for world’s first dual glucose-ketone sensing technology for people with diabetes
• Positive Sentiment: Updated American Cancer Society guidelines reaffirmed Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options, reinforcing Abbott’s position in cancer diagnostics. ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
• Neutral Sentiment: Abbott’s diagnostics unit showed mixed first-quarter trends, with core lab growth offset by weakness in China and softer respiratory testing demand, suggesting an uneven outlook in that segment. How Abbott’s Diagnostics Unit Is Shaping Up Through the Rest of 2026
• Negative Sentiment: Goldman Sachs lowered its price target on Abbott to $113 from $121, even while maintaining a buy rating, adding some caution around near-term upside. Goldman Sachs adjusts price target on Abbott Laboratories to 113 from 121, maintains buy rating
• Negative Sentiment: Separately, commentary highlighted headwinds in Abbott’s nutrition business, which may be weighing on investor sentiment. Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $85.70 on Thursday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The stock has a 50 day moving average of $95.41 and a 200-day moving average of $111.15. The company has a market capitalization of $149.27 billion, a P/E ratio of 24.00, a P/E/G ratio of 1.45 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the company posted $1.09 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Insider Activity at Abbott Laboratories

In other news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 3,055 shares of company stock worth $353,097 in the last three months. 0.46% of the stock is owned by company insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.